Cargando…

Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)

BACKGROUND: Cardioembolic stroke (CES) due to atrial fibrillation (AF) is associated with high stroke mortality. Oral anticoagulation (OAC) reduces stroke mortality, however, the impact of OAC-administration during hospital stay post ischemic stroke on mortality is unclear. We determined whether the...

Descripción completa

Detalles Bibliográficos
Autores principales: Palm, Frederick, Kraus, Martin, Safer, Anton, Wolf, Joachim, Becher, Heiko, Grau, Armin J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196130/
https://www.ncbi.nlm.nih.gov/pubmed/25294430
http://dx.doi.org/10.1186/s12883-014-0199-7
_version_ 1782339429570969600
author Palm, Frederick
Kraus, Martin
Safer, Anton
Wolf, Joachim
Becher, Heiko
Grau, Armin J
author_facet Palm, Frederick
Kraus, Martin
Safer, Anton
Wolf, Joachim
Becher, Heiko
Grau, Armin J
author_sort Palm, Frederick
collection PubMed
description BACKGROUND: Cardioembolic stroke (CES) due to atrial fibrillation (AF) is associated with high stroke mortality. Oral anticoagulation (OAC) reduces stroke mortality, however, the impact of OAC-administration during hospital stay post ischemic stroke on mortality is unclear. We determined whether the timing of OAC initiation among other prognostic factors influenced mortality after CES. METHODS: Within the Ludwigshafen Stroke Study (LuSSt), a prospective population-based stroke register, we analysed all patients with a first ever ischemic stroke or TIA due to AF from 2006 until 2010. We analysed whether treatment or non-treatment with OAC and initiation of OAC-therapy during and after hospitalization influenced stroke mortality within 500 days after stroke/TIA due to AF. RESULTS: In total 479 patients had a first-ever ischemic stroke (n = 394) or TIA (n = 85) due to AF. One-year mortality rate was 28.4%. Overall, 252 patients (52.6%) received OAC. In 181 patients (37.8%), OAC treatment was started in hospital and continued thereafter. Recommendation to start OAC post discharge was given in 110 patients (23.0%) of whom 71 patients received OAC with VKA (14.8%). No OAC-recommendation was given in 158 patients (33.0%). In multivariate Cox regression analysis, higher age (HR 1.04; 95% CI 1.02-1.07), coronary artery disease (HR: 1.6; 95% CI 1.1-2.3), higher mRS-score at discharge (HR 1.24; 95% CI 1.09-1.4), and OAC treatment ((no OAC vs started in hospital (HR: 5.4; 95% CI 2.8-10.5), were independently associated with stroke mortality. OAC-timing did not significantly influence stroke mortality (started post discharge vs. started in hospital (HR 0.3; 95% CI 0.07-1.4)). CONCLUSIONS: OAC non-treatment is the main predictor for stroke mortality. Although OAC initiation during hospital stay showed a trend towards higher mortality, early initiation in selected patients is an option as recommendation to start OAC post hospital was implemented in only 64.5%. This rate might be elevated by implementation of special intervention programs.
format Online
Article
Text
id pubmed-4196130
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41961302014-10-15 Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt) Palm, Frederick Kraus, Martin Safer, Anton Wolf, Joachim Becher, Heiko Grau, Armin J BMC Neurol Research Article BACKGROUND: Cardioembolic stroke (CES) due to atrial fibrillation (AF) is associated with high stroke mortality. Oral anticoagulation (OAC) reduces stroke mortality, however, the impact of OAC-administration during hospital stay post ischemic stroke on mortality is unclear. We determined whether the timing of OAC initiation among other prognostic factors influenced mortality after CES. METHODS: Within the Ludwigshafen Stroke Study (LuSSt), a prospective population-based stroke register, we analysed all patients with a first ever ischemic stroke or TIA due to AF from 2006 until 2010. We analysed whether treatment or non-treatment with OAC and initiation of OAC-therapy during and after hospitalization influenced stroke mortality within 500 days after stroke/TIA due to AF. RESULTS: In total 479 patients had a first-ever ischemic stroke (n = 394) or TIA (n = 85) due to AF. One-year mortality rate was 28.4%. Overall, 252 patients (52.6%) received OAC. In 181 patients (37.8%), OAC treatment was started in hospital and continued thereafter. Recommendation to start OAC post discharge was given in 110 patients (23.0%) of whom 71 patients received OAC with VKA (14.8%). No OAC-recommendation was given in 158 patients (33.0%). In multivariate Cox regression analysis, higher age (HR 1.04; 95% CI 1.02-1.07), coronary artery disease (HR: 1.6; 95% CI 1.1-2.3), higher mRS-score at discharge (HR 1.24; 95% CI 1.09-1.4), and OAC treatment ((no OAC vs started in hospital (HR: 5.4; 95% CI 2.8-10.5), were independently associated with stroke mortality. OAC-timing did not significantly influence stroke mortality (started post discharge vs. started in hospital (HR 0.3; 95% CI 0.07-1.4)). CONCLUSIONS: OAC non-treatment is the main predictor for stroke mortality. Although OAC initiation during hospital stay showed a trend towards higher mortality, early initiation in selected patients is an option as recommendation to start OAC post hospital was implemented in only 64.5%. This rate might be elevated by implementation of special intervention programs. BioMed Central 2014-10-08 /pmc/articles/PMC4196130/ /pubmed/25294430 http://dx.doi.org/10.1186/s12883-014-0199-7 Text en © Palm et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Palm, Frederick
Kraus, Martin
Safer, Anton
Wolf, Joachim
Becher, Heiko
Grau, Armin J
Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)
title Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)
title_full Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)
title_fullStr Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)
title_full_unstemmed Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)
title_short Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)
title_sort management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (lusst)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196130/
https://www.ncbi.nlm.nih.gov/pubmed/25294430
http://dx.doi.org/10.1186/s12883-014-0199-7
work_keys_str_mv AT palmfrederick managementoforalanticoagulationaftercardioembolicstrokeandstrokesurvivaldatafromapopulationbasedstrokeregistrylusst
AT krausmartin managementoforalanticoagulationaftercardioembolicstrokeandstrokesurvivaldatafromapopulationbasedstrokeregistrylusst
AT saferanton managementoforalanticoagulationaftercardioembolicstrokeandstrokesurvivaldatafromapopulationbasedstrokeregistrylusst
AT wolfjoachim managementoforalanticoagulationaftercardioembolicstrokeandstrokesurvivaldatafromapopulationbasedstrokeregistrylusst
AT becherheiko managementoforalanticoagulationaftercardioembolicstrokeandstrokesurvivaldatafromapopulationbasedstrokeregistrylusst
AT grauarminj managementoforalanticoagulationaftercardioembolicstrokeandstrokesurvivaldatafromapopulationbasedstrokeregistrylusst